The Hindu Business Line : Lupin buoyed by expansion plans

The stock of Lupin Ltd has been gaining of late on the back of `buy' recommendation by several broking houses. The stock gained close to eight per cent on a week-on-week basis. However, it ended on Thursday lower by 0.64 per cent at Rs 891.95 (Rs 897.70) on the BSE.

According to marketmen, broking houses are positive on the company's plans to increase its presence in the European generic market through partnerships and the company continues to aggressively spend on research and development.

Besides, traders are also betting on the recent approval got by Lupin from the Drugs Controller General (India) to conduct Phase-II clinical trials for its psoriasis pure compound LL-42 18 (Desoside-P). The total market for psoriasis — a chronic skin condition that has defied treatment all these days — is estimated to be more than $2 billion. The company also has three other new chemical entities in various stages of clinical trials.

K.S. Badri Narayanan

More Stories on : Stock Markets | Stocks | Ear to the ground | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Time-scale modes blamed for monsoon disparities

Pvt role likely in uranium mining

HC reserves order on Hutch plea

Qualcomm gets notice for service tax on royalty

Bharti signs $100-m deal with IBM

Iran-Pak-India gas pipeline project stuck on pricing

Sugar prices, stocks surge on DGFT notification

`Top Indian cos ahead of MNCs'

Jet Airways: In rough weather

Lupin buoyed by expansion plans

SEBI norms for MF overseas investment

`Offshore engg services is the next big thing'